Herpes Zoster Vaccination in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Vaccine Efficacy, Effectiveness, and Safety.

Authors

Sukamto Koesnoe, Evy Yunihastuti, Alvina Widhani, Suzy Maria, Anshari Saifuddin Hasibuan, Bramantya Wicaksana, Diski Saisa, Utariny Nurin Nasywa, Indira Laksmi Maharani

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109198. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of herpes zoster (HZ) due to immune dysregulation and immunosuppressive therapy. This systematic review aimed to evaluate the vaccine efficacy/effectiveness (VE) and safety outcomes of the HZ vaccine in patients with IMIDs.
PubMed, Cochrane Library, and Scopus were searched for clinical trials and cohort studies evaluating recombinant zoster vaccine (RZV) or zoster vaccine live (ZVL) in adults with IMIDs. Effect sizes were expressed as VE% and risk ratio (RR) with 95% confidence intervals (CIs). Random-effects meta-analyses used restricted maximum likelihood estimation.
Twenty-six studies involving 2,238,638 patients with various IMIDs were included. RZV efficacy was 90.5% (69.1%-97.1%), while effectiveness was 59.0% (49.8%-66.5%). ZVL effectiveness was 42.4% (37.1%-47.3%). RZV reduced post-herpetic neuralgia, with VE of 33.6% (11.7%-50.0%). Disease flares were not increased significantly in RZV (RR 1.05 [0.91-1.22]) and ZVL (RR 1.29 [0.69-2.43]). Reactogenicity and systemic adverse events were more frequent following HZ vaccination, particularly with RZV.
HZ vaccination, especially RZV, effectively prevents HZ in patients with IMIDs and is generally well tolerated. These findings support RZV use while emphasizing individualized assessment of vaccination timing and immunosuppressive treatment. Further studies should examine long-term effectiveness and safety across IMID subtypes and immunosuppressive regimens.

PMID:
42896729
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.